Yener Serkan, Tuna Gamze, Kant Melis, Akis Merve, Kara Ozlem, Kalas Busra, Baris Mustafa, Islekel Gul Huray
Division of Endocrinology, Dokuz Eylul University, Izmir, Turkey.
Department of Molecular Medicine, Dokuz Eylul University, Izmir, Turkey.
Horm Metab Res. 2021 Nov;53(11):752-758. doi: 10.1055/a-1661-4126. Epub 2021 Nov 5.
Autonomous cortisol secretion (ACS) of an adrenal incidentaloma (AI) is associated with mild cortisol excess that could result in poor metabolic and cardiovascular outcomes. The biological activity of glucocorticoids depends on the unbound, free fraction. We aimed to evaluate plasma free cortisol (FC) concentrations in patients with ACS in this cross-sectional study. One hundred and ten AI patients in 3 groups; non-functioning (NFA, n=33), possible ACS (n=65), ACS (n=12) were enrolled. Following measurements were conducted: Clinical data and total serum cortisol (TC), plasma corticotrophin (ACTH), serum dehydroepiandrosterone sulfate (DHEA-S), cortisol after 1 mg dexamethasone by both immunoassay and LC-MS/MS (DexF), serum corticosteroid binding globulin (CBG), plasma dexamethasone concentration [DEX] and plasma FC by LC-MS/MS. Patients with ACS featured an unfavorable metabolic profile. Plasma [DEX] and serum CBG levels were similar between groups. Plasma FC was significantly higher in ACS when compared to NFA and possible ACS groups p<0.05 and p<0.01, respectively. In multiple regression analysis DexF (beta=0.402, p<0.001) and CBG (beta=-0.257, p=0.03) remained as the independent predictors of plasma FC while age, sex, BMI, smoking habit, and existing cardiovascular disease did not make a significant contribution to the regression model. In conclusion, the magnitude of cortisol excess in ACS could lead to increased plasma FC concentrations. Further studies in AI patients are needed to demonstrate whether any alterations of cortisol affinity for CBG exist and to establish whether plasma FC concentrations predict the unfavorable metabolic profile in ACS.
肾上腺偶发瘤(AI)的自主性皮质醇分泌(ACS)与轻度皮质醇过量有关,这可能导致不良的代谢和心血管结局。糖皮质激素的生物活性取决于未结合的游离部分。在这项横断面研究中,我们旨在评估ACS患者的血浆游离皮质醇(FC)浓度。110例AI患者分为3组:无功能组(NFA,n = 33)、可能的ACS组(n = 65)、ACS组(n = 12)。进行了以下测量:临床数据、血清总皮质醇(TC)、血浆促肾上腺皮质激素(ACTH)、血清硫酸脱氢表雄酮(DHEA-S)、通过免疫测定和液相色谱-串联质谱法(LC-MS/MS)检测的1 mg地塞米松后的皮质醇(DexF)、血清皮质类固醇结合球蛋白(CBG)、血浆地塞米松浓度[DEX]以及通过LC-MS/MS检测的血浆FC。ACS患者具有不良的代谢特征。各组之间血浆[DEX]和血清CBG水平相似。与NFA组和可能的ACS组相比,ACS组的血浆FC显著更高,p分别<0.05和p<0.01。在多元回归分析中,DexF(β = 0.402,p<0.001)和CBG(β = -0.257,p = 0.03)仍然是血浆FC的独立预测因子,而年龄、性别、BMI、吸烟习惯和现有的心血管疾病对回归模型没有显著贡献。总之,ACS中皮质醇过量的程度可能导致血浆FC浓度升高。需要对AI患者进行进一步研究,以证明皮质醇与CBG的亲和力是否存在任何改变,并确定血浆FC浓度是否可预测ACS中的不良代谢特征。